PHARNEXT: Shareholder Letter: Time to reveal Pharnext true v

PARIS, France, January 11th, 2023, 8:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for rare

Related Keywords

Phoenix , Arizona , United States , Paris , France General , France , Canada , Israel , Schwann , Baden Wüberg , Germany , Fabreguettes Leib , Hugo Brugi , Sukaina Virji , Xavier Paoli , James Kuo , Joshua Schafer , Mary Jane Elliott , Rob Quinn , Alexandra Harrison , Company On , Edison Investment Research , Financial Press Relation , Euronext Growth Stock Exchange , Media Relations International , Consilium Strategic Communications , Chief Executive Officer , Overall Neuropathy Limitation Scale , Open Label Extension , Managing Director , Healthcare Ventures , Charcot Marie Tooth Disease Type , Overall Neuropathy Limitations Scale , Meter Walk Test , Quantified Muscular Testing , Patient Global Impression , Charcot Marie Tooth Neuropathy Score , Charcot Marie Tooth Disease , Shows Sustained Benefit , Announces On Schedule Completion , Patient Enrollment , Pivotal Phase , Announces First Patient Enrolled , Pharnext , Shareholder , Setter , Dime , Reveal , True , Value ,